Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00305734 · ClinicalTrials.gov registry record · Phase 2
Bortezomib and Gemcitabine in Treating Patients With Recurrent or Metastatic Nasopharyngeal Cancer
A Phase 2 study of Recurrent Nasopharyngeal Cancer and Stage IV Nasopharyngeal Cancer, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT00305734 is a Phase 2 study of Recurrent Nasopharyngeal Cancer and Stage IV Nasopharyngeal Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 50 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00305734, a Phase 2 study of Recurrent Nasopharyngeal Cancer and Stage IV Nasopharyngeal Cancer, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial is studying how well giving bortezomib together with gemcitabine works in treating patients with recurrent or metastatic nasopharyngeal cancer. Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving bortezomib together with gemcitabine may kill more tumor cells
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- DRUG bortezomib
- DRUG gemcitabine hydrochloride
Study Locations (1)
Texas
- Southwest Oncology Group - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2006-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00305734
The ClinicalTrials.gov registry entry for NCT00305734 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Recurrent Nasopharyngeal Cancer appearing as the primary indexed condition, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00305734 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00305734 about?
NCT00305734 is a clinical study titled "Bortezomib and Gemcitabine in Treating Patients With Recurrent or Metastatic Nasopharyngeal Cancer". This phase II trial is studying how well giving bortezomib together with gemcitabine works in treating patients with recurrent or metastatic nasopharyngeal cancer. Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such a...
What is the current status of trial NCT00305734?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2006-08.
What conditions does trial NCT00305734 study?
This clinical trial studies the following conditions: Recurrent Nasopharyngeal Cancer, Stage IV Nasopharyngeal Cancer.
What interventions are being tested in trial NCT00305734?
The interventions under investigation include: laboratory biomarker analysis (OTHER), bortezomib (DRUG), gemcitabine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00305734?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00305734 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.